View Older Stories View More Recent Stories

Jan 5, 2024 07:00AM Genprex Provides Business Update and Outlook for 2024
Nov 1, 2023 07:30AM Genprex to Present at BIO-Europe 2023 Conference
Oct 20, 2023 07:30AM Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Oct 4, 2023 12:00PM Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 7, 2023 07:30AM Genprex to Present at Upcoming September Investor Conference
Aug 22, 2023 07:30AM Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Aug 10, 2023 07:30AM Genprex (GNPX) Granted FDA Orphan Drug Designation for REQORSA
Aug 10, 2023 07:30AM Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
Jul 21, 2023 04:15PM Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 19, 2023 08:02AM Genprex (GNPX) sells 7.425M shares at $1.01 w/warrants
Jul 19, 2023 08:00AM Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 18, 2023 08:37AM Genprex (GNPX) Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jul 18, 2023 08:37AM Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jul 5, 2023 08:35AM Genprex (GNPX) Granted Chinese Patent for REQORSA Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
Jul 5, 2023 08:35AM Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
Jun 28, 2023 08:35AM Genprex (GNPX) Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for Treatment of Small Cell Lung Cancer
Jun 28, 2023 08:35AM Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
May 30, 2023 07:30AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tagrisso® in Advanced NSCLC
May 30, 2023 07:30AM Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
May 25, 2023 05:00PM Genprex (GNPX) Publishes Positive Data from Phase 1 Portion of Acclaim-1 Trial Evaluating REQORSA
May 25, 2023 05:00PM Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
May 23, 2023 07:30AM Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System
May 8, 2023 07:30AM Genprex to Participate and Present at Upcoming May Industry and Investor Conferences
Apr 19, 2023 09:11AM Genprex (GNPX) Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX
Apr 19, 2023 09:11AM Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
Apr 18, 2023 09:13AM Genprex (GNPX) Reports Independent Research Showing TUSC2 Functions as a Novel Tumor Suppressor for Glioblastoma
Apr 18, 2023 09:11AM Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Mar 23, 2023 07:30AM Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies
Mar 13, 2023 07:30AM Genprex to Present at Bioprocessing Summit Conference
Mar 8, 2023 07:30AM Genprex to Participate in March Investor and Industry Conferences
Feb 27, 2023 08:31AM Genprex (GNPX) Announces 3.81M Share Placement at $1.05/sh
Feb 27, 2023 08:30AM Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor
Feb 23, 2023 07:02AM Genprex (GNPX) Announces Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes
Feb 23, 2023 07:00AM Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatme
Jan 5, 2023 07:03AM Genprex (GNPX) Enters Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jan 5, 2023 07:00AM Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jan 4, 2023 07:00AM Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes
Dec 15, 2022 07:01AM Genprex (GNPX) Licenses Additional Technology from University of Pittsburgh
Dec 15, 2022 07:00AM Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Dec 14, 2022 07:00AM Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Canc
Dec 2, 2022 08:15AM Genprex to Present at Upcoming December Investor Conference
Oct 7, 2022 07:45AM Genprex to Present at Upcoming October Investor and Industry Conferences
Sep 8, 2022 08:15AM Genprex to Present at Upcoming September Investor Conference
Aug 16, 2022 07:01AM Genprex (GNPX) Granted US Patent for REQORSA Immunogene Therapy
Aug 16, 2022 07:00AM Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers
Aug 15, 2022 07:00AM Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Jul 13, 2022 07:00AM Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Jun 2, 2022 07:00AM Genprex to Present at Upcoming June Investor Conferences
May 19, 2022 08:15AM Genprex to Present at Upcoming Investor Conference in May 2022
May 9, 2022 08:15AM Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
View More Recent Stories View Older Stories